Clinical professor
Department of Surgery
Faculty of Medicine

Dr. Michele Lodde trained in urology at the University Clinic for Urology of the University of Vienna (Universitätsklinik für Urologie, Medizinische Universität Wien) (Vienna, Austria) under the supervision of Dr. Michael Marberger. After his residency, Dr. Lodde completed, from 2007 to 2009, a subspecialty in uro-oncology at the CHU de Québec-Université Laval (Québec, Canada) under the supervision of Dr. Yves Fradet. After working for 5 years at the Urology Clinic of Bolzano Hospital (Bolzano, Italy), in 2014 he joined the urology department of the CHU de Québec-Université Laval as a uro-oncologist.

Since the beginning of his career, the research carried out by Dr. Lodde has been aimed at improving clinical practices. During his residency and the years following his specialization, Dr. Lodde was involved in research aimed at improving the diagnosis, classification, and prognosis of cancers. Most of his research has been focused on bladder cancer. One of his most important contributions to the field of urology to date was the evaluation of different tests to aid in the diagnosis of bladder cancer. His research focused in particular on evaluating the performance of the ImmunoCyt/uCyt+ test and its potential in the clinical management of bladder cancer. All these analyses led to the publication of 11 articles which were frequently cited.

During his subspecialty, Dr. Lodde was also interested in the clinical importance of positron emission tomography using 18F-fluorodeoxyglucose as a tracer (18F-FDG PET/CT scan) in the assessment of urothelial cancer. The article summarizing this work had a strong impact in the field of urology.

Other studies by Dr. Lodde aimed to improve the classification of superficial bladder tumors into two categories: low- and high-risk cancers. The same concept was taken up by the World Health Organization (WHO) in the new classification with the change of the cytological grade system from 3 categories to 2 categories (high and low grades).

Finally, several other research studies by Dr. Lodde aimed at surgical improvements in bladder cancer. The advantages and disadvantages of en-bloc resection of the bladder tumor have been demonstrated. Dr. Lodde also investigated methods of teaching surgical techniques to residents. Since his beginnings in Quebec, he has participated in several research studies for the improvement of post-operative treatment in patients who have undergone a cystectomy, participated, and coordinated studies aimed at improving trans-urethral resection of the bladder (RESECT STUDY) and intravesical therapy of bladder cancer with Gemcitabine and Taxotere. He is an active member of the Canadian Bladder Cancer Information System group (pan-Canadian prospective database on bladder cancer diagnoses and treatment). He supervised the research of several residents on the effect of the pandemic on the follow-up of patients in urology and the use of analgesia in post-operative urology.

In recent years, he has added to his clinical and research activities the rare pathology of penile cancer.

In total, Dr. Lodde has published more than 70 articles and made more than 60 oral or poster presentations.